RecruitingPhase 2NCT07537868

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction: A Randomized Controlled Trial

Sponsor

October 6 University

Enrollment

80 participants

Start Date

Apr 20, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Myocardial Infarction (AMI)

Summary

This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University

Eligibility

Min Age: 30 YearsMax Age: 75 Years

Inclusion Criteria1

Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent

Exclusion Criteria14

Chronic use of anti-inflammatory drugs
Severe hepatic or renal impairment
Hypersensitivity to Montelukast
Autoimmune or inflammatory diseases
Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture
Having received cardiopulmonary resuscitation
Severe and inadequately controlled hypertension
History of myocardial infarction
Concomitant active bleeding or visceral hemorrhage
Concomitant malignant tumors, lymphomas, leukemias, or other diseases
gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug
Family history of psychiatric disorders
Pregnancy or lactation
Participation in another clinical trial